Key statistics dashboard for Precision BioSciences, Inc. (DTIL). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Precision BioSciences, Inc. is a clinical-stage biotechnology firm based in the United States, specializing in the creation of both in vivo gene editing solutions and ex vivo allogeneic CAR T-cell therapies. At its core is ARCUS, a proprietary genome editing platform designed to address and potentially cure genetic diseases.
Stock Data
| Price | $6.63 |
| Market Cap | $85M |
| Enterprise Value | $27.1M |
| Beta | 1.09 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -2.38 |
| Price / Book | 3.78 |
| P/S | 1.89 |
| EV/EBITDA | -0.54 |
| EV/Sales | 0.60 |
| EV/FCF | -0.52 |
| P/FCF | -1.64 |
| Earnings Yield | -30.76% |
| FCF Yield | -61.08% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 100.00% |
| EBIT Margin | -116.07% |
| EBITDA Margin | -111.09% |
| Operating Margin | -80.78% |
| Net Margin | -117.04% |
| Return on Equity | -91.60% |
| Return on Assets | -41.88% |
| Return on Invested Capital | -30.23% |
| Return on Capital Employed | -30.64% |
Financial Health
| Current Ratio | 12.82 |
| Quick Ratio | 12.82 |
| Cash Ratio | 12.06 |
| Debt / Equity | 0.62 |
| Debt / Assets | 22.32% |
| Net Debt / EBITDA | 1.16 |
| Interest Coverage | -27.55 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -4.31 |
Per-Share Data
| Revenue per share | 1.74 |
| Book Value per share | 1.75 |
| Cash per share | 3.39 |
| FCF per share | -2.01 |
| Tangible Book Value per share | 1.71 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 9 |
| Hold | 3 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 12 |
| Avg rating (1-5) | 0.75 |
Related companies: ABOS · ALEC · GOSS · HOOK · HRTX · KLDO · QTTB
Explore sector: Healthcare · Biotechnology
More sections of DTIL: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks